Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 7/20 | 0.55 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.54 |
| ▸ | FURIN | P09958 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.54 |
| ▸ | EED | O75530 | 1/20 | 0.52 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29598823 | 0.96 | NPY1R (0.58) | NPY1RNPY2RNPY4RNPBWR1OPRL1 | |
| SCHEMBL30729466 | 0.88 | NPY1R (0.59) | NPY1RNPY2RNPY4ROPRL1KISS1R | |
| SCHEMBL30769625 | 0.87 | OPRK1 (0.56) | NPBWR1KISS1ROPRK1 | |
| SCHEMBL30769588 | 0.85 | BACE1 (0.59) | KISS1R | |
| SCHEMBL30130346 | 0.83 | BACE1 (0.57) | — | |
| SCHEMBL31484077 | 0.83 | BACE1 (0.58) | — | |
| SCHEMBL29364756 | 0.83 | NPY1R (0.57) | NPY1RNPY2RNPY4RNPBWR1FURIN | |
| SCHEMBL30769622 | 0.83 | OPRK1 (0.56) | NPY1RNPY2RNPY4RKISS1ROPRK1 | |
| SCHEMBL31396396 | 0.83 | NPY1R (0.68) | NPY1RNPY2RNPY4REEDOPRK1 | |
| SCHEMBL29501591 | 0.82 | NPY4R (0.83) | NPY1RNPY2RNPY4RKISS1ROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250051763-A1 | METHODS AND SYSTEMS FOR CONDITIONALLY REGULATING GENE EXPRESSION | FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2025-02-13 | — | — | US | disclosed |
| US-20250019415-A1 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | MONASH UNIVERSITY (AU) | 2025-01-16 | — | — | US | disclosed |
| CN-119192295-A | Neurostatin cyclic peptide and preparation method and application thereof | 西北师范大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-111247163-B | Screening assays, modulators and modulators of progressive glycation end product Receptor (RAGE) activation | 莫纳施大学 | 2024-11-26 | — | — | CN | disclosed |
| US-12060408-B2 | Screening assays, modulators and modulation of activation of Receptor for Advanced Glycation End-products (RAGE) | MONASH UNIVERSITY (AU) | 2024-08-13 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240084335-A1 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240076624-A1 | Methods and Tools for Studying Enteroendocrine Cells | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2024-03-07 | — | — | US | disclosed |
| US-20240044871-A1 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2024-02-08 | — | — | US | disclosed |
| US-20230321146-A1 | CHIMERIC POLYPEPTIDES AND METHODS OF USING THE SAME | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2023-10-12 | — | — | US | disclosed |
| US-11773411-B2 | Chimeric proteins and methods of regulating gene expression | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220281989-A1 | GPCR BINDING PROTEINS AND SYNTHESIS THEREOF | Twist Bioscience Corporation | 2022-09-08 | — | — | US | disclosed |
| US-11407837-B2 | GPCR binding proteins and synthesis thereof | Twist Bioscience Corporation (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NPY1R 3820/4885NPY2R 3500/4885NPY4R 3663/4885 |
| US-12060408-B2 | Screening assays, modulators and modulation of activation of Receptor for Advanced Glycation End-products (RAGE) | AGER, GPR174, GRK2 | NPY1R 444/4885NPY2R 438/4885NPY4R 430/4885 |
| US-20250019415-A1 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | AGER, GPR174, GRK2 | NPY1R 444/4885NPY2R 438/4885NPY4R 430/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | NPY1R 1849/4885NPY2R 1995/4885NPY4R 2452/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NPY1R 3820/4885NPY2R 3500/4885NPY4R 3663/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | NPY1R 3330/4885NPY2R 2910/4885NPY4R 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.